Related Experiment Video
Updated: Jul 8, 2026

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
Published on: April 14, 2014
Clinical course of optic neuritis in patients with relapsing neuromyelitis optica
Regina Maria Papais-Alvarenga1, Sandro Carvalho Carellos, Marcos Papais Alvarenga
1Departamento de Neurologia, UNIRIO, Rua Mariz e Barros 775, Tijuca, 20270-004, Rio de Janeiro, RJ, Brazil. regina_alvarenga@hotmail.com
Objective:
To describe the clinical characteristics, course, and prognosis of optic neuritis in recurrent neuromyelitis optica.
Methods:
We analyzed 60 patients diagnosed using 1999 Mayo Clinic criteria who were seen between 1985 and 2004 at Hospital da Lagoa (Rio de Janeiro, Brazil).
Results:
Optic neuritis was the initial feature in 53.3% of patients, most with unilateral disease. Recurrent optic neuritis before myelitis occurred in 18.3%. The visual impairment was severe at nadir of the visual index event in 78.3%, with a high remission rate. In the median disease duration of 8 years (range, 0.5-30 years), 380 relapses (118 optic neuritis, 223 myelitis, 39 optic neuritis and myelitis) occurred. At the last follow-up, 53.3% of patients had bilateral visual impairment and 63.3% were blind in at least 1 eye. A high mortality rate (23.3%) was due to cervical myelitis. Mortality rates were significantly higher among Afro Brazilian patients (58.3%).
Conclusions:
Optic neuritis in patients with recurrent neuromyelitis optica has a severe and acute onset, with predominantly unilateral lesions followed by improvement of clinical symptoms. In the long-term, the disease leads to severe bilateral visual impairment. Mortality rates are higher among patients of Afro Brazilian descent.
Related Concept Videos
Multiple Sclerosis l: Introduction
Encephalitis ll: Pathophysiology
Arboviral Encephalitis
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
